12:00 AM
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bavituximab: Completed Phase I enrollment

Peregrine completed enrollment of an undisclosed number of patients in an open-label, dose-escalation Phase I trial evaluating bavituximab as monotherapy. The study...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >